HCW Biologics is trading 6.67% up at $2.08 in after-hours trading after broader biotech-sector strength, with the XBI ETF gaining 2.55% on September 18, 2026.

  • No new company-specific announcement was identified for September 18, 2026.
  • The latest material news was a September 8 exclusive Akron Biotech distribution agreement for HCW11-006, which appears stale relative to this session’s move.
  • Broader risk-on conditions supported the gain, while company-specific causation remains unconfirmed.